Wednesday, February 02, 2011

Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. To Provide Update on LibiGel Safety Study at International Society for the Study of Women's Sexual Health Meeting


LINCOLNSHIRE, Ill. - February 2, 2011 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that it will provide a LibiGel safety study update, and is supporting two clinical symposia at the Annual Meeting of The International Society for the Study of Women's Sexual Health Meeting (ISSWSH) being held from February 10-13, 2011 at the Doubletree Paradise Valley resort in Scottsdale, Arizona. More than 300 experts and practitioners in women's health and female sexual dysfunction (FSD) are expected to attend the meeting.
Michael Snabes, MD, PhD, BioSante's senior vice president of medical affairs, will deliver an oral presentation entitled, "LibiGel� (testosterone gel) Safety Study Continues with a Low Rate of Cardiovascular and Breast Cancer Events," on February 12, 2011 at 3 pm local time. Dr. Snabes will provide an update on the largest-ever safety study comparing low-dose testosterone treatment to placebo treatment, including the LibiGel safety study's low cardiovascular event rate. To date, this ongoing study has enrolled more than 2,800 menopausal women who suffer from Hypoactive Sexual Desire Disorder (HSDD).
The supported symposia are entitled, "Efficacy of Testosterone in Treating Women with HSDD" and "FSD and the FDA: Past, Present & Future." The first symposium, "Efficacy of Testosterone in Treating Women with HSDD," will feature Susan R. Davis, MBBS, FRACP, PhD, Professor of Women's Health and NHMRC Principal Research Fellow and Director, the Women's Health Research Program, Department of Medicine, Monash University, Vic, Australia, and Glenn Braunstein, MD, Department of Medicine, Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California.
The second symposium, "FSD and the FDA: Past, Present & Future," will be moderated by Alan Altman, MD, president of ISSWSH. The speakers include Anita H. Clayton, MD, professor of psychiatry and neurobehavioral sciences, and professor of clinical obstetrics and gynecology at the University of Virginia Health Systems; Michael Krychman, MD, medical director of The Sexual Medicine Center in Hoag Hospital in Newport Beach, California; Marianne Brandon, PhD, a clinical psychologist for Wellminds Wellbodies LLC and a diplomat in sex therapy; Julia Heiman, PhD, director of the Kinsey Institute for Research in Sex, Gender, and Reproduction and professor of psychology and clinical psychiatry at Indiana University, as well as Dr. Snabes of BioSante.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, future market size, acceptance and potential of LibiGel and other statements identified by words such as "will," "potential," "could," "would," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Media:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Investors:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.

No comments: